Risk factors for invasive mold infections following allogeneic hematopoietic stem cell transplantation: A single center study of 190 recipients

References

• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100: 4358–66.
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909–17.
   PubMed Web of Science ®Google Scholar
• Rabagliati BR, Fuentes LG, Guzmán DA, Orellana UE, Oporto CJ, Aedo CI, . Invasive fungal disease in hemato-oncological and hematopoietic stem cell transplantation patients from Hospital Clinico Universidad Católica, Santiago-Chile using revised EORTC/MSG diagnostic criteria. Rev Chilena Infectol 2009;26:212–9.
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008;47:1041–50.
   PubMed Web of Science ®Google Scholar
• Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997;175:1459–66.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, . Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010;50:1091–100.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Raiola AM, Bruno B, Furfaro E, Van Lint MT, Bregante S, . Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplant 2009;44:361–70.
   PubMed Web of Science ®Google Scholar
• Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295–304.
   PubMed Web of Science ®Google Scholar
• Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, . Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980;69:204–17.
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, . Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7–14.
   PubMed Web of Science ®Google Scholar
• Horn DL, Fishman JA, Steinbach WJ, Anaissie EJ, Marr KA, Olyaei AJ, . Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007;59:407–14.
   PubMed Web of Science ®Google Scholar
• Post MJ, Lass-Floerl C, Gastl G, Nachbaur D. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 2007;9:189–95.
   PubMed Web of Science ®Google Scholar
• Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, . Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009;48: 265–73.
   PubMed Web of Science ®Google Scholar
• Morgan J, Wannemuehler KA, Marr KA, Hadley S, Kontoyiannis DP, Walsh TJ, . Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005;43:S49–58.
   PubMed Web of Science ®Google Scholar
• Waldorf AR, Levitz SM, Diamond RD. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 1984;150:752–60.
   PubMed Web of Science ®Google Scholar
• Roilides E, Uhling K, Venzon D, Pizzo PA, Walsh TJ. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993;61:4870–7.
   PubMed Web of Science ®Google Scholar
• Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology 1994;140:2475–9.
   PubMed Web of Science ®Google Scholar
• Sainz J, Hassan L, Perez E, Romero A, Moratalla A, López-Fernández E, . Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary aspergillosis. Immunol Lett 2007;109:76–82.
   PubMed Web of Science ®Google Scholar
• Sainz J, Pérez E, Hassan L, Moratalla A, Romero A, Collado MD, . Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. Hum Immunol 2007;68:41–50.
   PubMed Web of Science ®Google Scholar
• Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, Janer M, . Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008;359:1766–77.
   PubMed Web of Science ®Google Scholar
• Rosenhagen M, Feldhues R, Schmidt J, Hoppe-Tichy T, Geiss HK. A risk profile for invasive aspergillosis in liver transplant recipients. Infection 2009;37:313–9.
   PubMed Web of Science ®Google Scholar
• Laursen AL, Mogensen SC, Andersen HM, Andersen PL, Ellermann-Eriksen S. The impact of CMV on the respiratory burst of macrophages in response to Pneumocystis carinii. Clin Exp Immunol 2001;123:239–46.
   PubMed Web of Science ®Google Scholar
• Baron M, Davignon JL. Inhibition of IFN-gamma-induced STAT1 tyrosine phosphorylation by human CMV is mediated by SHP21. J Immunol 2008;181:5530–6.
   PubMed Web of Science ®Google Scholar
• Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z. Human cytomegalovirus inhibits maturation and impairs function of monocyte-derived dendritic cells. Blood 2002;99:2913–21.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J, . Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006;91:78–83.
   PubMed Web of Science ®Google Scholar
• Larsson K, Aschan J, Remberger M, Ringdén O, Winiarski J, Ljungman P. Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus. Transplantation 2004;77:526–31.
   PubMed Web of Science ®Google Scholar
• Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531–40.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, . Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010;50:1559–67.
   PubMed Web of Science ®Google Scholar